Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

Discoid Lupus Erythematosus Clinical Trial

Official title:

Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00691769
• Other study ID #: IRB00000301
• Secondary ID: 31050
• Status: Completed
• Start date: April 26, 2006
• Est. completion date: November 26, 2012

Study information

• Verified date: July 2018
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this research study is to see if a specific protein that we are interested in is involved in scarring hair loss. If these proteins are involved, further genetic work may also better define the disease as well as future treatment options.

Description:

This is a single-center study, designed to evaluate the expression of Fas protein in skin biopsies of patients with scarring alopecia including fourteen patients with central centrifugal scarring alopecia (CCSA), three patients with lichen planopilaris (LP) and three patients with discoid lupus erythematosus (DLE). Skin biopsies of five healthy participants will be used as controls.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: November 26, 2012
• Est. primary completion date: November 26, 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• Participants ages 30 years or older with a biopsy- proven diagnosis of CCSA.

• Undergone standard of care treatment for CCSA by a WFUSM Dermatologist

• Women of child bearing age will be required to have a negative pregnancy test in order to participate in the study

• Participants ages 30 years or older with a biopsy- proven diagnosis of LP.

• Participants ages 30 years or older with a biopsy- proven diagnosis of DLE.

• Healthy participants must be ages 30 years or older.

Exclusion Criteria:

• Age less than 30 years of age.

• Clinically evident bacterial or viral infection of the scalp.

• Pregnant or nursing woman of child-bearing potential.

• Participation in any other investigative research study involving study medication.

• Inability to return for the biopsy visit.

Related Conditions & MeSH terms

• Alopecia
• Alopecia Areata
• Central Centrifugal Scarring Alopecia
• Cicatrix
• Discoid Lupus Erythematosus
• Lichen Planopilaris
• Lupus Erythematosus, Discoid

Locations

Country	Name	City	State
United States	Wake Forest University Health Sciences Dermatology	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Wake Forest University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia (CCSA), lichen planopilaris (LP) and discoid lupus erythematosus (DLE) and in healthy controls.		8 weeks
Secondary	To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia before and after treatment with intralesional and topical steroids.		8 weeks